Aagami has received a new assignment from a new client for strategic advisory and partnership development.

Client is a bio-targeted nanomedicines company with world-wide exclusive rights to a novel and innovative drug-targeting platform technology developed at Cedars-Sinai Medical Center in Los Angeles.

The technology is based on generating self-assembling bio-targeted nanoparticles, called Eosomes. The structural basis of the Eosomes is a recombinant protein that has three functional domains:
1) receptor binding 2) endosomal penetration and 3) therapeutic capture

The Eosomes protein binds the therapeutic through noncovalent electrostatic interaction driving the self-assembly of the Eosomes.